Janssen submits HCV combo to FDA

Share this article:

J&J's Janssen submitted a supplemental new drug application for HCV treatment Olysio (simeprevir) combined with sofosbuvir today for the treatment of genotype 1 patients with liver scarring (fibrosis).

Simeprevir was approved in November 2013 for patients with chronic HCV in combination with peginterferon and ribavirin. The drug was co-developed by Medivir AB.

MM&M reported in November that Janssen was “committed to patient education” for the drug, and would also offer diagnostic testing to providers in a bid to improve access.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.